A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
Clinical trial NCT05355051 · RECRUITING
Trial details
- NCT number
- NCT05355051
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-05
- Primary completion
- 2026-12-31
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.